Norwegian version of this page

Experimental Immunotherapy

Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer.

To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells.

Our goals

We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy.

The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners.​


Published Oct. 14, 2019 1:44 PM - Last modified Mar. 25, 2020 12:37 PM


Group leader


Detailed list of participants